Skip to main content
Download PDF

Outcomes of hospitalized hematologic oncology patients receiving rapid response system activation for acute deterioration: another time, another way

Critical Care volume 23, Article number: 419 (2019) Cite this article

The Original Article was published on 27 August 2019

Dear Editor,

We have read the recent article written by Gershkovich et al. [1]. In this paper, the authors sought to examine the outcomes of hospitalized hematologic oncology patients requiring rapid response system (RRS) activation after clinical deterioration and to identify the factors that are independently associated with in-hospital mortality. The authors concluded that hematologic oncology patients who are admitted to the hospital and suffer an acute deterioration experience high rates of ICU admission and in-hospital mortality.

In recent years, there has been an increase in the number of hematologic oncology patients admitted to ICUs. Currently, this condition is no longer a criterion to dismiss admission to the ICU [2]. Due to the continuous increase in the number of these patients and the complexity of their disease, we developed in 2012 a new strategy to optimize the management of this type of patients. We considered that RRS did not reflect accurately the severity of their condition. To date, the role of these alert systems is not yet clearly established [1].

Our strategy is based on daily multidisciplinary ward rounds with hematologists and intensivists in order to identify the high-risk patients and to admit them early to the ICU. The association between early versus late ICU admission and improved survival in hematologic oncology patients has been previously established [3]. Our data before (2000–2011) and after (2012–2016) implementation shows the following:

  1. 1.

    An 8% increase in the total number of admissions to critical care after implementation

  2. 2.

    Reduction of in-ICU mortality, 90-day mortality, and post 90-day mortality (44%, 54%, and 62% in the 2012–2016 period) as compared with the pre-implementation period (53%, 61%, and 66%)

According to Azoulay et al. [3], teamwork and high-quality communication between hematologists and intensivists improve patient management. In our center, this new strategy of early admission of high-risk hematologic oncology patients resulted in a higher number of admissions and a lower mortality both in the ICU and after ICU and hospital discharge.

These promising outcomes have led to a new collaboration agreement with the Oncology Department with the final aim of replicating these results in patients with solid tumors.

Since the RRS has not yet demonstrated improved outcomes in the hematologic oncology patients, we believe that our model could be a valid alternative to those by facilitating an early admission to critical care, improving outcomes and being cost neutral.

Availability of data and materials

The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Gershkovich B, Fernando SM, Herritt B, Castellucci LA, Rochwerg B, Munshi L, et al. Outcomes of hospitalized hematologic oncology patients receiving rapid response system activation for acute deterioration. Crit Care. 2019;23:286.

    Article  Google Scholar 

  2. Azoulay E, Soares M, Darmon M, Benoit D, Pastores S, Afessa B. Intensive care of the cancer patient: recent achievements and remaining challenges. Ann Intensive Care. 2011;1(1):5.

    Article  Google Scholar 

  3. Azoulay E, Pène F, Darmon M, Lengliné E, Benoit D, Soares M, et al. Managing critically ill hematology patients: time to think differently. Blood Rev. 2015;29(6):359–67.

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable

Funding

None

Author information

Authors and Affiliations

  1. Servicio de Medicina Intensiva, Hospital Universitario La Paz-Carlos III-Cantoblanco, IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain

    Belén Civantos, José Manuel Añón, Santiago Yus, María José Asensio & Abelardo García-de-Lorenzo

  2. CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain

    José Manuel Añón

Authors
  1. Belén Civantos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. José Manuel Añón
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Santiago Yus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. María José Asensio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Abelardo García-de-Lorenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

BC, MJA, and AGDL contributed to the initial concept and design. BC, SY, and JMA participated in the data analysis and the final draft of the manuscript. All authors read and approved the final manuscript.

Authors’ information

Not applicable

Corresponding author

Correspondence to Belén Civantos.

Ethics declarations

Ethics approval and consent to participate

Comité Ético de Investigación Clínica (Ethical Committee of Clinical Research), Hospital Universitario La Paz, IdiPAZ, Madrid, Spain. Reference number CEIm: PI-3894

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This comment refers to the article available at https://doi.org/10.1186/s13054-019-2568-5.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Civantos, B., Añón, J.M., Yus, S. et al. Outcomes of hospitalized hematologic oncology patients receiving rapid response system activation for acute deterioration: another time, another way. Crit Care 23, 419 (2019). https://doi.org/10.1186/s13054-019-2714-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13054-019-2714-0

Keywords

  • Malignancy
  • Critical care
  • Hematology
  • Mortality